Development of an enzyme immunoassay to detect and quantitate tumor-associated antigens in the urine of sarcoma patients

J. F. Huth, R. K. Gupta, D. L. Morton

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This study describes the development of an enzyme immunoassay (EIA) to quantitate antigen in the urine of sarcoma patients and compares its results with those of the authors' previously reported complement fixation assay. Three populations were studied for the presence of urinary antigen by EIA: (1) sarcoma patients who developed metastatic disease after resection of their primary tumor; (2) sarcoma patients who remain clinically disease-free two years after resection disease-free two years after resection of their primary tumor; and (3) normal volunteers with no history of malignant disease. Each group consisted of nine individuals. None of the urines from normal volunteers and none from sarcoma patients who remained free of disease for two years had elevated antigen titers detectable by EIA. However, all nine patients who developed pulmonary metastatic disease had significantly elevated levels of antigen in their urine prior to clinical evidence of disease recurrence. The day-to-day fluctuations in antigen titer detectable by EIA tended to parallel the levels detected by the complement fixation assay. However, EIA detected a significant elevation in antigen titer one to four months earlier than the complement fixation assay in four of the patients in whom disease recurred.

Original languageEnglish (US)
Pages (from-to)2856-2861
Number of pages6
JournalCancer
Volume47
Issue number12
StatePublished - 1981

Fingerprint

Neoplasm Antigens
Immunoenzyme Techniques
Sarcoma
Urine
Antigens
Healthy Volunteers
Lung Diseases
Neoplasms
Recurrence
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Development of an enzyme immunoassay to detect and quantitate tumor-associated antigens in the urine of sarcoma patients. / Huth, J. F.; Gupta, R. K.; Morton, D. L.

In: Cancer, Vol. 47, No. 12, 1981, p. 2856-2861.

Research output: Contribution to journalArticle

@article{71f2f6b12b3942368c437e3acb2b4ade,
title = "Development of an enzyme immunoassay to detect and quantitate tumor-associated antigens in the urine of sarcoma patients",
abstract = "This study describes the development of an enzyme immunoassay (EIA) to quantitate antigen in the urine of sarcoma patients and compares its results with those of the authors' previously reported complement fixation assay. Three populations were studied for the presence of urinary antigen by EIA: (1) sarcoma patients who developed metastatic disease after resection of their primary tumor; (2) sarcoma patients who remain clinically disease-free two years after resection disease-free two years after resection of their primary tumor; and (3) normal volunteers with no history of malignant disease. Each group consisted of nine individuals. None of the urines from normal volunteers and none from sarcoma patients who remained free of disease for two years had elevated antigen titers detectable by EIA. However, all nine patients who developed pulmonary metastatic disease had significantly elevated levels of antigen in their urine prior to clinical evidence of disease recurrence. The day-to-day fluctuations in antigen titer detectable by EIA tended to parallel the levels detected by the complement fixation assay. However, EIA detected a significant elevation in antigen titer one to four months earlier than the complement fixation assay in four of the patients in whom disease recurred.",
author = "Huth, {J. F.} and Gupta, {R. K.} and Morton, {D. L.}",
year = "1981",
language = "English (US)",
volume = "47",
pages = "2856--2861",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Development of an enzyme immunoassay to detect and quantitate tumor-associated antigens in the urine of sarcoma patients

AU - Huth, J. F.

AU - Gupta, R. K.

AU - Morton, D. L.

PY - 1981

Y1 - 1981

N2 - This study describes the development of an enzyme immunoassay (EIA) to quantitate antigen in the urine of sarcoma patients and compares its results with those of the authors' previously reported complement fixation assay. Three populations were studied for the presence of urinary antigen by EIA: (1) sarcoma patients who developed metastatic disease after resection of their primary tumor; (2) sarcoma patients who remain clinically disease-free two years after resection disease-free two years after resection of their primary tumor; and (3) normal volunteers with no history of malignant disease. Each group consisted of nine individuals. None of the urines from normal volunteers and none from sarcoma patients who remained free of disease for two years had elevated antigen titers detectable by EIA. However, all nine patients who developed pulmonary metastatic disease had significantly elevated levels of antigen in their urine prior to clinical evidence of disease recurrence. The day-to-day fluctuations in antigen titer detectable by EIA tended to parallel the levels detected by the complement fixation assay. However, EIA detected a significant elevation in antigen titer one to four months earlier than the complement fixation assay in four of the patients in whom disease recurred.

AB - This study describes the development of an enzyme immunoassay (EIA) to quantitate antigen in the urine of sarcoma patients and compares its results with those of the authors' previously reported complement fixation assay. Three populations were studied for the presence of urinary antigen by EIA: (1) sarcoma patients who developed metastatic disease after resection of their primary tumor; (2) sarcoma patients who remain clinically disease-free two years after resection disease-free two years after resection of their primary tumor; and (3) normal volunteers with no history of malignant disease. Each group consisted of nine individuals. None of the urines from normal volunteers and none from sarcoma patients who remained free of disease for two years had elevated antigen titers detectable by EIA. However, all nine patients who developed pulmonary metastatic disease had significantly elevated levels of antigen in their urine prior to clinical evidence of disease recurrence. The day-to-day fluctuations in antigen titer detectable by EIA tended to parallel the levels detected by the complement fixation assay. However, EIA detected a significant elevation in antigen titer one to four months earlier than the complement fixation assay in four of the patients in whom disease recurred.

UR - http://www.scopus.com/inward/record.url?scp=0019459290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019459290&partnerID=8YFLogxK

M3 - Article

C2 - 7020919

AN - SCOPUS:0019459290

VL - 47

SP - 2856

EP - 2861

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -